Gilead Sciences’ controversial $1,000-a-day Sovaldi pill is priced in line with previous treatments for Hepatitis C, but the nation’s health-care system likely won’t be able to handle that kind of sticker shock, and competition probably will bring down that price tag in coming months and years. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 4.84% in last session and finished the day at $89.19. Traded volume … Continue reading Investors Alert – Gilead Sciences (NASDAQ:GILD) , Galena Biopharma (NASDAQ:GALE) , RPI , UnitedHealth (NYSE:UNH) , China Automotive (NASDAQ:CAAS)